On Thursday, Intellia Therapeutics Inc NTLA outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z. NTLA-2002 is advancing in the pivotal Phase 3 HAELO study for HAE, following promising Phase 2 results demonstrating the potential to eliminate chronic treatments after a one-time infusion. Meanwhile, nex-z has shown robust results in the Phase 3 MAGNITUDE study for ATTR amyloidosis, with clinical evidence suggesting the therapy could halt or re ...

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Florida on behalf of all persons or entities who purchased or otherwise acquired Micron Technology, Inc. (“Micron Technology” or the “Company”) (NASDAQ: MU) securities between September 28, 2023 and December 18, 2024, inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or mislead ...

New York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in these private offerings of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc., raising an aggregate total of $875,500 through the transactions. The private placements were suc ...

The common shares and the common shares issuable upon the conversion of related warrants have not been registered under the Securities Act of 1933, as amended, or any state securities laws. Until registered, these securities may not be offered or sold in the United States or any state absent registration or an applicable exemption from registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in a ...

New York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in these private offerings of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc., raising an aggregate total of $875,500 through the transactions. The private placements were s ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly six months since my last Nuvalent (NASDAQ: NUVL ) article , where I discussed NVL-655’s blockbuster potential following the FDA’s decision to grant the company’s ALK-selective inhibitor, NVL-655 their Breakthrough Therapy Designation ...

Toyota is making big moves in the rapidly developing EV market. Is the Japanese giant changing with the times, or leading the charge? Here' s what you need to know.You probably don't think of Toyota Motor (TM -3.91%) as a maker of electric vehicles (EVs). The Japanese automaker has been a dominant force in traditional gas cars for nearly a century. Toyota was a pioneer in hybrid vehicles, and the Prius is still a big seller after 27 years on the global market.Toyota's electrifying EV salesBut the times, the ...

SUNNYVALE, Calif., Jan. 10, 2025 /PRNewswire/ -- Today, Synopsys issued the following statement in response to the European Commission (EC) approving its proposed acquisition of Ansys in Phase 1: Synopsys headquarters in Sunnyvale, Calif. (PRNewsfoto/Synopsys, Inc.) "We are very pleased that the EC has approved our pro-competitive transaction in Phase 1. Today's clearance decision follows the strong progress we have made toward gaining regulatory approval across various jurisdictions. Earlier this week, the ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Cardinal Health (CAH) . This company, which is in the Zacks Medical - Dental Supplies industry, shows potential for another earnings beat. This prescription drug distributor has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters ...